Pasithea Therapeutics Corp. Common Stock KTTA · Stock Open Pasithea Therapeutics Corp. Common Stock in new tab
Pasithea Therapeutics Corp. Common Stock Analysis (KTTA)
Is Pasithea Therapeutics Corp. Common Stock a good investment? Pasithea Therapeutics Corp. Common Stock (KTTA) is currently trading at 0.5104 USD.
Earnings Schedule: Pasithea Therapeutics Corp. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.46.
Investor FAQ
Does Pasithea Therapeutics Corp. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pasithea Therapeutics Corp. Common Stock?
Pasithea Therapeutics Corp. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.39.
Company Profile
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 2, 2024 | 1:20 |
Community Discussion